TMTangyou Mao

Tangyou Mao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tangyou Mao has a total of 118 co-authors. Here are the top co-authors by number of shared publications:

  • Junxiang Li

    Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, People’s Republic of China

    11 shared publications
  • Yali Yuan

    Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China; Hebei North University, Zhangjiakou, Hebei, China

    11 shared publications
  • Muyuan Wang

    Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, People’s Republic of China

    10 shared publications
  • Yitong Li

    Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, People’s Republic of China

    10 shared publications
  • Zhibin Wang

    Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, People’s Republic of China

    10 shared publications
  • Wenji Zhang

    Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China

    9 shared publications

Latest Publications

  • Open Access

    Integrative animal model and pilot clinical study reveal the therapeutic effects and mechanisms of Modified Wumei Pill against intestinal inflammation

    by Muyuan Wang, Jiayan Hu, Zhibin Wang, Lei Shi, Rui Shi, Chengtao Liang, Yitong Yu, Yuxi Wang, Chenran Lv, Zhengdao Lin, et al.

  • Longitudinal Gut Microbiota Changes in Mouse Models of Chronic Colitis, Colitis‐Associated Cancer, and Chemotherapy‐Induced Diarrhea

    by Juncong Hu, Anqi Yang, Xinru Li, Mingxu Gao, Jiayan Hu, Hao Huang, Luyue Wang, Yue Dong, Zeyu Xue, Tangyou Mao, et al.

    Background: Gut microbiota contributes to intestinal pathologies, but microbial and metabolic differences distinguishing inflammation‐associated tumorigenesis from chronic colitis remain unclear. This study mapped stage‐dependent microbiota dynamics and metabolic perturbations across three independent mouse models: chronic ulcerative colitis (CUC), AOM/DSS‐induced colitis‐associated cancer (CAC), and chemotherapy‐induced diarrhea (CID). Methods: CUC, CAC, and CID were induced by cyclic DSS, AOM/DSS, and CPT‐11, respectively. Disease progression was monitored via endoscopy, histopathology, and Disease Activity Index. Gut microbiota was profiled by 16S rRNA sequencing across three stages (R01–R03); metabolic and inflammatory changes were assessed by RT‐qPCR and metabolite assays. Mediation analysis was used to explore whether the associations between microbial abundance and host metabolic/inflammatory markers were statistically consistent with an indirect pathway. Results: CID showed distinct acute transient injury and a unique microbiota structure separate from CUC/CAC. In CUC and CAC, microbiota restructured stage‐dependently: beneficial genera ( Akkermansia ) declined, while pathobionts ( norank_o_Clostridia_UCG‐014 ) increased. CAC showed upregulation of glycolysis genes (HK2, PKM2, LDHA, Glut1) together with elevated colonic lactate concentrations, and elevated colonic concentrations of the pro‐inflammatory cytokines IL‐17A and IL‐22, indicating distinct colonic metabolic and inflammatory changes associated with gut dysbiosis. Mediation analysis showed that norank_o__Clostridia_UCG‐014 showed consistently positive indirect effects, irrespective of the glycolytic enzyme and lactate enantiomer examined; and Allobaculum had a consistently positive indirect effect on both IL‐17A and IL‐22. Conclusion: These findings reveal distinct stage‐specific microbial and metabolic signatures distinguishing AOM/DSS tumor‐bearing mice from nonneoplastic chronic colitis and acute chemotherapy intestinal injury.

  • Faecalibaculum rodentium- derived quinic acid- mediated Treg differentiation drives the attenuation intestinal inflammation by Agrimoniae Herba polysaccharides

    by Jiayan Hu, Yitong Yu, Zhibin Wang, Muyuan Wang, Yuxi Wang, Xiaowei Chen, Yuyue Liu, Mengyu Zheng, Chengtao Liang, Chenran Lv, et al.


  • Open Access

    Association between blood selenium level and nonalcoholic fatty liver disease among naturally menopausal women: A cross-sectional study

    by Chen Chen, Yitong Yu, Jiayan Hu, Gang Zheng, Junxiang Li, Chune Xie, Zhibin Wang, Xiaowei Chen, Mengyu Zheng, Chengtao Liang, et al.

    Nonalcoholic fatty liver disease (NAFLD) is a growing health burden worldwide. The association between blood selenium (Se) and NAFLD in naturally menopausal women remains unclear. This study aimed to evaluate the association of blood Se levels with the prevalence of NAFLD, hepatic steatosis, and liver fibrosis in the US naturally menopausal women population. This study analyzed the dataset from the 2017 to 2018 National Health and Nutrition Examination Survey, including 595 naturally menopausal women. Weighted logistic regression models were used to evaluate the cross-sectional association between blood Se levels and the prevalence of NAFLD. Linear regression and ordinal logistic regression were used to evaluate the association between blood Se levels and liver steatosis and fibrosis. All analyses were conducted using the R survey package. There were no significant associations of blood Se levels with NAFLD in 3 adjusted models (odds ratio [OR] = 0.52, 95% confidence interval [CI], 0.04–7.11; OR = 0.66, 95% CI, 0.04–9.82; OR = 0.79, 95% CI, 0.08–8.08). However, in the fully adjusted model, blood Se levels showed a negative association with liver fibrosis (β = −2.32, 95% CI, −4.21, −0.43). Participants were divided into quartiles (Q1–Q4) based on the distribution of blood Se concentrations within the study cohort. The specific cutoff points were Q1 group (<173.67 μg/L), Q2 group (173.67 to <189.15 μg/L), Q3 group (189.15 to <204.35 μg/L), and Q4 group (≥204.35 μg/L). Compared with the reference group (Q1 group, <173.67 μg/L), significant inverse associations were also found for the higher Se groups (Q3 group: OR = 0.23, 95% CI, 0.1–0.53; Q4 group: OR = 0.28, 95% CI, 0.12–0.66). Our results showed that blood Se levels were not significantly associated with the prevalence of NAFLD in a US population of naturally menopausal women, but higher blood Se levels were negatively associated with liver fibrosis. Further research is needed to assess the causal relationship between exposure and disease risk.

  • Oral rhein attenuate nonalcoholic steatohepatitis in mice through the modulation of gut microbiota and Th17 cell differentiation

    by Yali Yuan, Jiayan Hu, Xinyu Lu, Haixiao Han, Muyuan Wang, Wenji Zhang, Yao Jiao, Yitong Li, Zhengdao Lin, Chengtao Liang, et al.


  • Open Access

    The impact of red meat and processed meat consumption on the risk of development and relapse of ulcerative colitis: a systematic review and dose-response meta-analysis

    by Yangyang Zhang, Yitong Yu, Ziyun Jiang, Junhong Yu, Zeyang Zhang, Zhuojia An, Yanhong Du, Yiqing Mao, Lanshuo Hu, Xudong Tang, et al.

    Background: Consumption of red and processed meats has been classified as probably carcinogenic and carcinogenic to humans, respectively. However, the association between their consumption and the incidence or recurrence of ulcerative colitis (UC) remains unclear. This study aims to systematically evaluate the dose–response relationship between red or processed meat consumption and UC.Methods: Databases including PubMed, Cochrane Library, Web of Science, Embase, CNKI, VIP, Wanfang, SinoMed, Yiigle, and ICTRP were searched from inception through July 2024. Pooled relative risks (RRs) with 95% confidence intervals (CIs) were estimated using random-effects or fixed-effects models based on heterogeneity. A dose-response meta-analysis was conducted using R 4.4.2.Results: Eighteen studies comprising 1,384,024 participants were included, all rated as moderate to high quality. Red meat consumption was significantly associated with an increased risk of UC development [RR = 1.21, 95% CI (1.03, 1.42), p = 0.020]. Processed meat consumption showed a tendency toward increased UC risk, although not statistically significant [RR = 1.54, 95% CI (0.99, 2.42), p = 0.058]. Neither red nor processed meat consumption was significantly associated with UC recurrence. Dose–response analysis indicated that each additional 100 g/day of red meat intake increased UC incidence risk by 65% [RR = 1.65, 95% CI (1.30, 2.09)].Conclusion: Based on very low-certainty evidence, increased red meat intake may be associated with a potential risk of developing UC. However, there is currently insufficient evidence to support an association between red or processed meat consumption and the recurrence of UC. Future studies with long-term follow-up and rigorous design are warranted to verify these findings and explore underlying mechanisms.Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024573557, identifier (CRD42024573557).


  • Open Access

    Immunological pathogenesis of inflammatory bowel disease: focus on tissue resident memory T cells

    by Jiayan Hu, Wenting Wang, Muyuan Wang, Chunye Wu, Yao Jiao, Yitong Li, Wenji Zhang, Chengtao Liang, Zhengdao Lin, Yitong Yu, et al.

    Tissue-resident memory T (TRM) cells are a type of tissue-restricted memory T cells with terminal differentiation and a memory function. They exist in mucosal tissues for a long period. In the absence of disease, TRM cells promote essential inflammation, which reinforces the intestinal barrier and prevents bacterial translocation. However, in inflammatory or autoimmune environments, TRM cells are hyperactivated. This heightened activity causes the host to release excessive pro-inflammatory cytokines, resulting in local immune imbalances and damage to the barrier, ultimately leading to tissue lesions. Numbers of studies have shown that TRM cells play a crucial role in the development and progression of inflammatory bowel disease (IBD), suggesting that targeted regulation of TRM cells homeostasis may be an important strategy for treating IBD. Here, we compiled the existing understanding of the role of TRM cells in IBD, with particular emphasis on the associated mechanisms and approaches for targeting TRM cells in IBD treatment. This review will serve as a foundation for a better understanding of IBD development and enhancing the effectiveness of clinical treatments for IBD.


  • Open Access

    Gut microbiota‐derived butyrate mediates the anticolitic effect of indigo supplementation through regulating CD4+ T cell differentiation

    by Yunqi Xing, Muyuan Wang, Yali Yuan, Jiayan Hu, Zhibin Wang, Zhongmei Sun, Mengyu Zheng, Lei Shi, Junxiang Li, Tangyou Mao

    This study explored the effect of plant‐derived indigo supplementation on intestinal inflammation using in vivo, in vitro, and clinical sample analyses. Our results showed that indigo decreased mucosal inflammation by regulating CD4+ T cell differentiation in a gut microbiota‐dependent manner. Microbes transferred from indigo‐treated mice, indigo‐induced enrichment of Roseburia intestinalis, and its metabolite butyrate played a role in Th17/Treg immunity similar to that of indigo in intestinal inflammation, which was involved in mTORC1/HIF‐1α signal‐mediated reprogrammed glucose metabolism. We further showed that patients with ulcerative colitis exhibited significant gut dysbiosis and CD4+ T cell differentiation abnormalities. Our findings provide new insights into the gut‐immune axis in ulcerative colitis, offering a novel microbial‐based immunotherapy for the treatment of inflammatory bowel disease.


  • Open Access

    Mendelian randomization study of circulating leukocytes counts reveals causal associations with inflammatory bowel disease

    by Chengtao Liang, Zhibin Wang, Yuhe Mai, Junxiang Li, Qiuhong Dai, Yali Yuan, Muyuan Wang, Yuyue Liu, Wenji Zhang, Yitong Li, et al.

    Inflammatory bowel disease (IBD) is a chronic recurrent IBD, whose cause involves the interaction between genetic and environmental factors. Although there is a recognized link between immune response and IBD, the causal relationship between circulating immune cell counts and IBD remains controversial. This study aimed to elucidate the causal relationship between genetically predicted circulating immune cell counts and IBD. We conducted a bidirectional 2-sample Mendelian randomization (MR) study using aggregated statistics from genome-wide association studies. The causal relationship between 5 circulating leukocytes cells (monocytes, lymphocytes, eosinophils, basophils and neutrophils) counts and IBD, including ulcerative colitis (UC) and Crohn disease (CD) was analyzed. Horizontal pleiotropy test and heterogeneity test were used to ensure the stability of the results. Our findings indicated that monocytes, lymphocytes, eosinophils, and basophils count were not significantly associated with IBD, however, elevated circulating neutrophils count was significantly associated with higher risk of IBD [odds ratio (OR) = 1.0017; 95% confidence interval (CI) = 1.0004–1.003; P = .009] and UC [OR = 2.465; 95% CI = 1.236–4.916; P = .01]. In addition, we also found that IBD [OR: 12.07; 95% CI = 1.909–76.316; P = .008] and CD [OR = 1.014; 95% CI = 1.004–1.023; P = .005] were significantly associated with higher circulating neutrophils count in reverse MR. This MR study provides genetic evidence for the causal relationship between the genetically predicted increase in circulating neutrophils count and the risk of IBD (UC and CD). This finding stresses the need for further exploring physiological functions of neutrophils in order to develop effective strategies against IBD.

  • Open Access

    Efficacy and safety of New Wumei Pill in the treatment of mesalazine-refractory ulcerative colitis: Study protocol for a randomized, double-blind, placebo-controlled trial

    by Wenji Zhang, Muyuan Wang, Yuyue Liu, Zhibin Wang, Yali Yuan, Pei Deng, Yupu Yao, Xiaowei Chen, Chengtao Liang, Zhengdao Lin, et al.

    Background: Mesalazine preparations serve as first-line therapy for active mild-to-moderate ulcerative colitis (UC), however, not all patients respond to mesalazine. Patients with mesalazine-refractory UC often switch to corticosteroids, immunological therapy, and biological agents, but their use is limited owing to their well-characterised side effects (e.g. osteoporosis and cushingoid feature). Therefore, there is an unmet medical need for novel treatments with a manageable safety profile for patients with mesalazine-refractory UC. New Wumei Pill is a novel and effective herbal prescription for the treatment of UC, and our preliminary study suggested that New Wumei Pill has a significant effect on patients with mesalazine-refractory UC. However, its effectiveness and safety has not been evaluated convincingly. Objectives: This trail aims to evaluate efficacy, safety and mechanisms of New Wumei Pill in the treatment of patients with mesalazine-refractory UC. Methods: This is a prospective, randomized, double-blind control trial, in which 72 patients with mesalazine-refractory mild-to-moderate UC will be randomized in a 1:1 ratio in the treatment and control group. Patients will be screened for eligibility at the outpatient and ward of the Department of Gastroenterology in Dongfang Hospital, Beijing University of Chinese Medicine. 72 participants will undergo strict screening to meet the diagnostic criteria of mildly to moderately active UC, with modified Mayo score of 3-10 points. All patients will be administered by mesalazine enteric-coated tablets for 8 weeks, at the same time, the patients in treatment group will receive New Wumei Pill, while patients from control group will be administered by dummy New Wumei Pill. Results: The primary outcomes are clinical efficacy rate and clinical remission rate according to the modified Mayo score. The secondary outcomes are individual symptom score, TCM syndrome score, endoscopic response rate, mucosal healing rate, and quality of life scale score. Finally, biological samples from participants will be preserved to reveal the mechanisms of New Wumei Pill on UC. Conclusions: We hypothesize that the patients with mesalazine-refractory mild-to-moderate UC will benefit from New Wumei Pill. If successful, this trial will provide evidence of traditional Chinese medicine in the treatment of UC, and hold promises for novel options UC patients and policymakers.